Expert Review of Neurotherapeutics

Papers
(The H4-Index of Expert Review of Neurotherapeutics is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
An overview of the differences in the pharmacological management of post-traumatic stress disorder between women and men46
The influence of anxiety and depression on headache in adolescent migraineurs: a case-control study40
Where Art Thou O treatment for diabetic neuropathy: the sequel40
Does electrical stimulation still have a place in the treatment armamentarium for Bell’s palsy?40
Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington’s disease38
The role of Fecal Microbiota Transplantation (FMT) in treating patients with multiple sclerosis34
Neuroprotective strategies in multiple sclerosis: a status update and emerging paradigms28
Laser interstitial thermal therapy for recurrent brain metastases following stereotactic radiosurgery: a systematic review27
The relevance of cortical thickness in migraine sufferers and implications to therapy26
New and emerging pharmacotherapeutic options for the treatment of lennox-gastaut syndrome: moving forward in 202526
Advances in the treatment and management of frontotemporal dementia25
Steps to manage treatment-refractory migraine in adults25
Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis25
The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives24
The latest developments with internet-based psychological treatments for depression24
How have the recent updated epilepsy classifications impacted on diagnosis and treatment?23
Why is ADHD so difficult to diagnose in older adults?23
Neonatal seizures treatment based on conventional multichannel EEG monitoring: an overview of therapeutic options23
Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents22
Managing antipsychotic-related sexual dysfunction in patients with schizophrenia22
Uncertainties in anti-amyloid monoclonal antibody therapy for Alzheimer’s disease: the challenges ahead21
0.098994016647339